Treatments to slow progression of autosomal dominant polycystic kidney disease: systematic review and meta-analysis of randomized trials (Q38181599)

30 August 2017

0 references

Treatments to slow progression of autosomal dominant polycystic kidney disease: systematic review and meta-analysis of randomized trials (English)

1 reference

autosomal dominant polycystic kidney disease

30 August 2017

main subject

1 reference

1 reference

autosomal dominant polycystic kidney

1 reference

1 reference

1 reference

30 August 2017

Thida M Myint

1 reference

30 August 2017

Gopi K Rangan

series ordinal

1 reference

30 August 2017

publication date

1 April 2014

1 reference

30 August 2017

1 reference

30 August 2017

1 reference

30 August 2017

1 reference

30 August 2017

page(s)

217-226

1 reference

Autosomal dominant polycystic kidney disease

30 August 2017

cites work

1 reference

Polycystic kidney disease

21 January 2018

1 reference

Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort

21 January 2018

1 reference

Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes

21 January 2018

1 reference

mTOR inhibition in autosomal-dominant polycystic kidney disease (ADPKD): the question remains open

21 January 2018

1 reference

Efficacy and safety of mTOR inhibitor therapy in patients with early-stage autosomal dominant polycystic kidney disease: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

Long-term treatment with mammalian target of rapamycin inhibitor does not benefit patients with autosomal dominant polycystic kidney disease: a meta-analysis.

21 January 2018

1 reference

Imaging for the prognosis of autosomal dominant polycystic kidney disease

21 January 2018

1 reference

Estimating the mean and variance from the median, range, and the size of a sample

21 January 2018

1 reference

Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease

21 January 2018

1 reference

Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease

21 January 2018

1 reference

Sirolimus and kidney growth in autosomal dominant polycystic kidney disease

21 January 2018

1 reference

Sirolimus therapy to halt the progression of ADPKD.

21 January 2018

1 reference

Everolimus in patients with autosomal dominant polycystic kidney disease.

21 January 2018

1 reference

Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease

21 January 2018

1 reference

The effect of eicosapentaenoic acid on renal function and volume in patients with ADPKD.

21 January 2018

1 reference

Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial

21 January 2018

1 reference

Sirolimus therapy for patients with adult polycystic kidney disease: a pilot study

21 January 2018

1 reference

mTOR Inhibitors and Autosomal Dominant Polycystic Kidney Disease

21 January 2018

1 reference

Long-term rapamycin therapy in the Han:SPRD rat model of polycystic kidney disease (PKD).

21 January 2018

1 reference

Autosomal dominant polycystic kidney disease: the last 3 years

21 January 2018

1 reference

Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease: What is the appropriate serum level?

21 January 2018

1 reference

Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease.

21 January 2018

1 reference

mTORC1/2 and rapamycin in female Han:SPRD rats with polycystic kidney disease

21 January 2018

1 reference

Somatostatin analog therapy for severe polycystic liver disease: results after 2 years

21 January 2018

1 reference

Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide

21 January 2018

1 reference

Polycystic kidney disease: Tolvaptan in ADPKD-TEMPO 3:4 trial results.

21 January 2018

1 reference

Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease.

21 January 2018

1 reference

Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease

21 January 2018

1 reference

Autosomal dominant polycystic kidney disease: modification of disease progression

21 January 2018

1 reference

Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months

21 January 2018

1 reference

Copeptin, a Surrogate Marker of Vasopressin, Is Associated with Disease Severity in Autosomal Dominant Polycystic Kidney Disease

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/NEP.12211

1 reference

30 August 2017

1 reference